💊 Everyone talks about AI discovering the next blockbuster drug. Few are talking about the $300 billion problem of getting those drugs to the right doctors.
That���s exactly what Synthio Labs is building for.
Speaking to Shereen Bhan on Young Turks Reloaded, co-founder Supreet Deshpande explains how AI could fundamentally reinvent pharma’s go-to-market engine-creating always-on, compliant AI experts that engage physicians at scale.
“You can’t solve the next generation of pharma with the last generation’s playbook.”
#AI #ArtificialIntelligence #Pharma #Healthcare #HealthTech #GenerativeAI #Startup #Innovation #Tech #SiliconValley #YoungTurksReloaded #CNBCTV18
@ShereenBhan | @sifytech |
A GOOD Q2FY24 RESULT HAS BEEN REPORTED BY CHOICE INTERNATIONAL, BUT PEERS LIKE ANGEL ONE ARE AVAILABLE AT MUCH CHEAPER AND ATTRACTIVE VALUATIONS 👍
Q2FY24 Net Profit Of 30 CR
VS
Q1FY24 Net Profit Of 21 CR
VS
Q2FY23 Net Profit Of 8 CR
Net profit growth of 43% QOQ & 275% YOY
Available at a forward PE of 36, valuation wise stock trades above fair valuation